(Press-News.org) NEW YORK, N.Y. — June 2. Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.
Lupus is a devastating heterogeneous autoimmune disease affecting millions worldwide with symptoms that can range from debilitating fatigue to life-threatening organ damage. Lupus Therapeutics and the Lupus Research Alliance are committed to advancing the identification and accelerating the development of potential new treatments for a community in urgent need of more options.
The three trials will evaluate the effectiveness and safety of ianalumab compared to placebo given as a subcutaneous injection once a month or every three months. All the three trials are already underway and enrolling lupus patients.
“We believe this collaboration between Lupus Therapeutics and Novartis Pharmaceuticals will provide a significant opportunity to accelerate the development of new treatments and therapies for both SLE and lupus nephritis conditions and are hopeful that this collaboration will pave the way for improved patient outcomes,” noted Lupus Therapeutics Executive Vice President Stacie Bell, Ph.D.
Click below to learn more about each trial.
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN) – Enrolling patients
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients with Systemic Lupus Erythematosus (SIRIUS-SLE 1) – Enrolling patients
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients with Systemic Lupus Erythematosus (SIRIUS-SLE 2) – Enrolling patients
About Lupus
Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90 percent of people with lupus are women; lupus most often strikes during the childbearing years of 15-45. Black/African Americans, Hispanic Americans, Asians and Native Americans are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints.
About Lupus Therapeutics
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, aims to accelerate the development of curative treatments for all patients living with lupus. Lupus Therapeutics collaborates with academic institutions, biotechnology and pharmaceutical partners through the unprecedented Lupus Clinical Investigators Network (LuCIN) to drive rapid and meaningful progress in the treatment of lupus patients. The organization elevates the patient voice, engages community stakeholders and strives for representation of the diverse lupus community in the clinical research process with the most innovative and renowned experts throughout North America. Visit lupustherapeutics.org for more information.
About the Lupus Research Alliance
The Lupus Research Alliance is the largest non-governmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering diverse scientific talent, and driving discovery toward better diagnostics, improved treatments and ultimately, cure for lupus. Because the Lupus Research Alliance’s Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.
END
Lupus Therapeutics partners to evaluate potential treatment for SLE and lupus nephritis through North American trial network
2023-06-02
ELSE PRESS RELEASES FROM THIS DATE:
Sensory adaptations to improve physiological, behavioral distress during dental visits in autistic children
2023-06-02
About The Study: In this randomized crossover trial of autistic children, using a sensory-adapted dental environment was safe and efficacious in decreasing physiological and behavioral distress during dental care. This is important because enhancing oral care is critical for autistic children; this intervention may also be beneficial for populations beyond autism.
Authors: Leah I. Stein Duker, Ph.D., O.T.R./L., of the University of Southern California in Los Angeles, is the corresponding author.
To access the embargoed study: Visit our For The Media website ...
Awareness of racial, ethnic bias and potential solutions to address bias with use of health care algorithms
2023-06-02
About The Study: This qualitative study found that participants perceived widespread and increasing use of algorithms in health care and lack of oversight, potentially exacerbating racial and ethnic inequities. Increasing awareness for clinicians and patients and standardized, transparent approaches for algorithm development and implementation may be needed to address racial and ethnic biases related to algorithms.
Authors: Peter Treitler, M.S.W., of Rutgers University in New Brunswick, New Jersey, is the corresponding author.
To ...
Reentry services may help stabilize substance use risks after mass prison release
2023-06-02
Contrary to expectations, the risk for relapses, overdoses and deaths related to substance use disorder didn’t increase after a large-scale prison release in New Jersey, according to a Rutgers study.
The study, published in JAMA Health Forum, examined whether post-release overdose deaths and drug-related hospital and emergency department visits increased after more than 2,000 individuals were released from prison in late 2020 as the result of a pandemic-era policy.
“Risk of relapse and adverse health events is high following prison release, with risk of fatal overdose ...
Memory killer cells can improve survival for melanoma patients
2023-06-02
Our skin contains specialised long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden and the University of Copenhagen in Denmark have now identified how these cells are formed, and shown that high levels of memory killer cells in cancer tissue correlate with a better survival rate in people with melanoma. The study is published in the journal Immunity.
Certain immune T cells called tissue-resident memory cells are formed locally in the skin and other tissue, and protect against infections that they have encountered before. Some of ...
HKUST researchers unveil long-sought noncanonical cleavage mechanism in miRNA biogenesis
2023-06-02
To discover and thoroughly demonstrate the newly identified noncanonical cleavage mechanism, the Hong Kong University of Science and Technology (HKUST) research team, led by Prof. Tuan Anh Nguyen, Assistant Professor of the Division of Life Science, used several sophisticated techniques, such as miRNA sequencing, pri-miRNA structure analysis, and high-throughput pri-miRNA cleavage assays for approximately 260,000 pri-miRNA sequences. In contrast to the canonical mechanism, the noncanonical mechanism does not rely on several essential protein and RNA elements ...
Immune system discovery could benefit spinal cord injuries
2023-06-02
New research suggests that the immune system’s ability to respond to spinal cord injuries diminishes with age – and identifies potential avenues to improve that response and help patients heal.
The new findings offer important insights into how the immune system responds to spinal-cord injuries, and why that response becomes blunted with the passing years. Further, it reveals an important role for the membranes surrounding the spinal cord in mounting the immune response to spinal-cord injury. With this information, doctors one day may be able to bolster the body’s natural immune response to improve patient outcomes, particularly among older adults.
“Recently, ...
UTHSC researchers’ work on human pangenome aids understanding of common chromosomal abnormality
2023-06-02
Researchers from the University of Tennessee Health Science Center have made a foundational discovery about chromosome biology through their work on the first-ever human pangenome reference.
Published recently by the Human Pangenome Reference Consortium in the journal Nature, the draft pangenome uses complete genome assemblies to provide a diverse look at the genetic makeup of humans. Researchers in the UTHSC Department of Genetics, Genomics and Informatics created the technical tools to build the pangenome, and then used the tools to understand variation in parts of the genome that could not be seen before.
The pangenome ...
Mysterious dashes revealed in Milky Way’s center
2023-06-02
New radio telescope images reveal hundreds of filaments along the galactic plane, each measuring 5 to 10 light-years in length
These structures likely originated a few million years ago when outflow from our supermassive black hole interacted with surrounding materials
Researcher: ‘I was actually stunned when I saw these’
EVANSTON, Ill. — An international team of astrophysicists has discovered something wholly new, hidden in the center of the Milky Way galaxy.
In the early 1980s, Northwestern University’s Farhad Yusef-Zadeh discovered gigantic, one-dimensional filaments dangling vertically near Sagittarius A*, our ...
ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer
2023-06-02
A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are a significant invasive disease-free survival benefit in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
Researchers found that patients who took the combination therapy had substantially longer invasive disease-free survival compared to those who were treated with the hormone therapy alone, regardless of whether the cancer has spread to the lymph nodes. The addition of the targeted therapy reduced the risk of recurrence by 25%.
The results were shared today during the American Society of Clinical ...
New research suggests wheat crops may be threatened by unprecedented heat and drought
2023-06-02
The world is getting hotter, causing shifts in seasonal patterns and increasing the amount of extreme weather such as severe droughts and heat waves, which can affect crop yields and food supplies. A recent study led by a researcher at the Friedman School of Nutrition Science and Policy at Tufts University found that the likelihood of extreme temperatures that could affect crop yields has increased significantly in wheat-producing regions of the U.S. and China.
The findings predict heat waves that happened approximately ...